Introduction
============

TNF plays a key role in the pathogenesis of rheumatoid arthritis (RA) and other auto-immune diseases. Several genetic variants in the *TNFA*gene, which codes for TNFα, have been investigated in relation to disease severity, but none of them appears to be highly specific and/or sensitive. The most thoroughly investigated *TNFA*polymorphism is the -308G \> A (rs1800629) located in the promoter of the gene, though studies focusing on this polymorphism have yielded conflicting results, \[[@B1]-[@B14]\].

Three studies \[[@B3],[@B6],[@B7]\] showed an association of the G allele with more pronounced radiologic joint damage. Other studies reported a worse radiologic outcome in patients carrying the A allele \[[@B1],[@B9],[@B13]\], or no association between the genetic variant and radiologic progression \[[@B2],[@B8]-[@B12],[@B14]\]. Given the contradictory results in these relatively small, individual studies, there is a need for a more comprehensive approach to evaluate the presence or absence of an association between the *TNFA*-308G \> A polymorphism and the severity of RA and radiological joint damage.

As the -308G \> A variant is located within the *TNFA*promoter, several studies have also investigated the polymorphism in relation to *TNFA*transcription, which could influence TNFα production and in turn, disease activity and severity \[[@B2],[@B15]-[@B23]\]. An important study by Knight *et al*., using the haploChIP method for high-throughput screening of common DNA polymorphisms that (might) effect gene regulation *in vivo*, reported that the -308G \> A polymorphism was not associated with *TNFA*expression in human B-cells \[[@B24]\]. A recent meta-analysis in healthy individuals (*n*= 1,825) shows that TNFα mRNA and protein levels are not influenced by the polymorphism \[[@B25]\].

Here, we first investigated the possible associations of the -308G \> A promoter polymorphism with disease activity, and radiologic joint damage after 3, 6 and 9 years follow-up in a large (*n*= 208), well-characterized cohort of patients with early RA \[[@B26]\]. Next, we performed a meta-analysis to draw more definitive conclusions on the role of the *TNFA*-308G \> A polymorphism in the severity of RA and radiological joint damage. This meta-analysis included a total of 2,053 patients and combined our data with previously published studies. To evaluate possible mechanisms underlying an association, we investigated gene expression in the different genotype groups in a cohort of 66 individuals with active RA.

Material and methods
====================

Ethics statement
----------------

The *Commissie Mensgebonden Onderzoek (CMO) Regio Arnhem Nijmegen*of the Radboud University Nijmegen Medical Centre approved the study (CMO number 2004/014). All patients had provided written informed consent prior to participation in the study. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

Patients
--------

All patients in this study fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA and attended the Department of Rheumatology of the Radboud University Nijmegen Medical Centre or the St. Maartenshospital in Nijmegen, The Netherlands.

The impact of the *TNFA*-308G \> A polymorphism on disease severity was analyzed using DNA isolated from blood of 208 patients from a long-term observational inception cohort with early RA \[[@B26]\]. Patients in this cohort have a disease duration \< 1 year and no prior use of DMARDs at enrollment. Disease activity was assessed using the 28-joint disease activity score (DAS28) at each 3-monthly visit. Radiologic joint damage at baseline and after 1, 2, 3, 6 and 9 years of disease duration was measured using radiographs of the hands and feet, read in chronological order by one of four raters according to the Ratingen score. The latter is a validated modification of the Larsen score and evaluates joint surface destruction, graded from 0 to 5, in 38 separate hand and foot joints (range 0 - 190) \[[@B27]\]. The intra-class correlation coefficient (ICC) for inter-rater reliability was 0.85; this was tested previously with the four raters in 10 patients over 9 years.

*TNFA*expression analysis was assessed in RNA from blood of 66 additional patients with active RA as defined by DAS28 \> 3.2. All patients attended the same hospital, and blood for RNA isolation was always collected between 9 and 10 o\'clock in the morning to avoid potential circadian fluctuations.

Molecular analysis
------------------

All DNA and RNA analyses were performed in a *Coördinatie Commissie ter bevordering van de Kwaliteitsbeheersing van het Laboratoriumonderzoek*(CCKL)-accredited laboratory at the department of Human Genetics at the Radboud University Nijmegen Medical Centre in Nijmegen.

Genotyping of the -308G \> A *TNFA*polymorphism
-----------------------------------------------

Genomic DNA was extracted from peripheral venous blood (10 ml/sample) according to standard protocols \[[@B28]\]. Both patient cohorts, thus, a total of 274 patients, were genotyped for the -308G \> A (rs1800629) promoter polymorphism using a TaqMan genotyping assay (ID: C7514879_10) on the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Results were analyzed using Allelic Discrimination software version 1.4 (Applied Biosystems).

RNA isolation, synthesis of cDNA and quantitative PCR
-----------------------------------------------------

RNA was isolated from whole blood within 30 minutes after collection, using the RNeasy midi kit (Qiagen Benelux BV Venlo, The Netherlands). The quality and quantity of the purified RNA was checked on a NanoDrop spectrophotometer (Nanodrop technologies, Montchanin, DE, USA). Degradation of RNA was controlled for by agarose gel electrophoresis. Per sample, 1 μg of total RNA was reverse-transcribed using 200 ng random hexanucleotides (Invitrogen, Breda, The Netherlands) and 200 units of moloney [m]{.ul}urine leukemia virus (M-MLV) Reverse Transcriptase (Invitrogen). For quantitative expression analysis a predesigned and validated gene-specific probe-based TaqMan gene expression assay (ID: Hs00174128_m1) was used according to the manufacturer\'s protocol (Applied Biosystems). Samples were run on the 7500 Fast Real-Time PCR System (Applied Biosystems) using standard protocols. The general housekeeping gene *B2M*(Beta-2-microglobulin, TaqMan gene expression assay ID: Hs99999907_m1) was used as the endogenous control. Threshold cycle numbers (referred to as Ct) were obtained using the 7500 System SDS software version 1.4 (Applied Biosystems). All samples were measured twice, and duplicate samples with a SD larger than 0.5 were excluded from the analysis. The relative quantity (RQ) of the gene-specific mRNA was calculated from the average value of the ΔCt ((*TNFA*Ct) - (endogenous control gene Ct)). Differences in expression between two groups of samples were calculated by the 2^ΔΔCt^method \[[@B29]\].

Statistical analysis
--------------------

Hardy-Weinberg equilibrium (HWE) was tested in both patient samples using the chi square test. Baseline differences between genotype groups were analyzed using the chi square test, Student\'s *t*-test or Wilcoxon test, as appropriate. Longitudinal analysis of radiologic joint damage in patients with RA was performed using generalized linear regression models with random coefficients (mixed models), allowing for analysis of repeated measures within a patient. The joint damage score was the dependent variable, genotype the independent variable, under addition of time, time squared and confounders. Regression assumptions were checked by evaluating the distribution of residuals and by a plot of observed and predicted joint damage scores. Mean differences in *TNFA*expression (ΔCt; (*TNFA*Ct) - (endogenous control gene Ct)) were analyzed using the independent Student\'s *t*-test.

A *P*-value \< 0.05 was considered statistically significant in each situation. Analyses were performed using SPSS for Windows, version 14.0 (SPSS, Chicago, IL, USA) and SAS version 8.2 (SAS Institute Inc., Cary, NC, USA).

Meta-analysis
-------------

Pubmed (up to March 31, 2012) was searched to identify publications investigating the effect of the -308G \> A polymorphism on joint damage. Using the search terms: 1) RA AND TNF AND (polymorphism or -308); 2) RA AND joint damage AND (polymorphism or TNF or -308 and TNF; 3) RA and erosions in combination with polymorphism and TNF or -308. The literature search yielded 292 papers, 37 of which reported on relevant primary analysis of the *TNFA*-308G \> A polymorphism. In order to be included in this meta-analysis, studies had to 1) include RA patients according to the ACR criteria, and 2) report on disease severity (presence or absence of erosions). Review manager 5 was used to perform a meta-analysis including 11 studies (10 published ones and this study) \[[@B1]-[@B10]\].

Homogeneity of odds ratios (ORs) among cohorts was calculated using the Breslow-Day method, and pooled ORs were calculated under a fixed and random effects model (Mantel-Haenszel meta-analysis).

Results
=======

Relation of *TNFA*-308G \> A with disease activity and radiologic joint damage
------------------------------------------------------------------------------

The frequency of the A allele in the inception cohort was 18.3%, genotype frequencies were 66.3% for the GG group, 30.8% for the GA group and 2.9% for the AA group. Due to the small AA genotype group, the GA and AA genotype groups were merged and analyzed as one group. Demographic and disease characteristics were similar in the GG and GA+AA genotype groups at baseline (Table [1](#T1){ref-type="table"}). No significant differences in disease activity were observed between genotype groups at baseline (*P*= 0.38) and after 3 (*P*= 0.85), 6 (*P*= 0.1) and 9 (*P*= 0.12) years of follow-up.

###### 

Demographics of the inception cohort (*n*= 208)

                                                    GG           GA+AA       
  ------------------------------------------- ----- ------------ ----------- ------
  Age, years, mean (SD)                             52 (13)      50 (13)     0.21
  Female gender, n (%)                              89 (64%)     50 (71%)    0.32
  RF positivity, n (%)                              105 (76%)    55 (79%)    0.69
  DAS28, mean (SD)                                                           
  Baseline                                    208   5.2 (1.4)    5.3 (1.3)   0.38
  3-year average                              208   4.0 (1.1)    3.9 (1.0)   0.85
  6-year average                              159   4.0 (1.0)    3.7 (1.0)   0.10
  9-year average                              115   4.0 (1.0)    3.7 (1.0)   0.12
  Patients with erosions at baseline, n (%)   208   76 (55%)     44 (63%)    0.28
  Ratingen score, median (range)                                             
  Baseline                                    208   0 (0-2)      0 (0-2)     0.17
  3 years                                     208   7 (0-15)     4 (0-10)    0.08
  6 years                                     160   12 (2-26)    10 (1-21)   0.18
  9 years                                     116   22 (10-38)   14 (3-24)   0.07

Percentages are expressed in relation to the total number of patients for each genotype group. RF, rheumatoid factor; DAS28, 28-joint disease activity score.

In the longitudinal regression analysis (mixed model) with radiologic joint damage as the dependent variable, a significant difference between the GG and GA+AA groups in the progression of joint damage was observed (Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). As shown in Table [2](#T2){ref-type="table"}, the progression of joint damage in the patients was 1.6 points per year, with progression rate slightly declining (-0.13 points) over the years of study. At baseline, the joint damage score of the genotype GA+AA group was on average 5 points lower (*P*= 0.002) than the score of the GG genotype group, corrected for age and DAS28 at baseline. There was no significant interaction between genotype and time of study, that is, the difference in joint damage score between genotype groups persisted during follow-up (*P*= 0.61), although in Figure [1](#F1){ref-type="fig"} it appears that the joint damage scores of both groups converge at year-9.

###### 

Longitudinal regression of joint damage and *TNFA*-308G \> A genotype (*n*= 208)

  Effect                  Estimate   Standard error (estimate)   *P*-value
  ----------------------- ---------- --------------------------- ------------
  Intercept               5.8        1.18                        \< 0.0001
  Genotype GA+AA          -5.0       1.62                        **0.0020**
  Year                    1.6        0.38                        \< 0.0001
  Year^2^                 -0.13      0.020                       \< 0.0001
  Genotype GA+AA × year   0.17       0.34                        **0.61**

Shown are the variables in the longitudinal regression analysis over 9 years, with joint erosion score as the dependent variable and *TNFA*-308G \> A or *TNFA*-308G \> A × year as primary dependent variables. Year^2^allows for a non-linear course of joint progression score over time. The analysis was corrected for gender, and time-averaged 28-joint disease activity score (DAS28), rheumatoid factor and age were not confounders.

![**Development of corrected joint scores over time showing the GG and GA+AA genotypes, separately**. Data points were calculated using the mixed model (least-square means and standard errors), including correction for age and 28-joint disease activity score (DAS28).](ar4110-1){#F1}

Since TNF might uncouple the relation between disease activity and joint damage \[[@B30]\], we assessed whether the use of TNF blocking agents was frequent in this patient population. The number of patients with past or present treatment with these agents was low, and was similar in both genotype groups (*n*= 20 (14%) and *n*= 12 (17%)) in the GG and GA+AA groups, respectively.

Meta-analysis
-------------

A total of 2,053 RA patients from 10 published studies, as well as the current one, were included in a meta-analysis to further confirm the observed association of TNF -308G \> A with joint damage, in this case defined as the presence or absence of erosions. Table [3](#T3){ref-type="table"} presents an overview of characteristics and the definition of erosions of the studies included in the meta-analysis. The analysis indeed confirmed that the -308G \> A polymorphism is statistically significantly associated with the presence of erosions (*P*= 0.04, OR 0.78, 95% CI 0.62, 0.98) (Figure [2](#F2){ref-type="fig"}), with patients carrying the GA/AA genotypes having less erosions. As we observed moderate heterogeneity, we also applied a random effects meta-analysis, producing a similar OR (0.86, 95% CI 0.58, 1.29).

###### 

Overview of the published studies included in the meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference               Population                                               N     Female, %   Age, years               **Disease duration**,\   Scoring method         Definition erosive disease
                                                                                                                              years                                           
  ----------------------- -------------------------------------------------------- ----- ----------- ------------------------ ------------------------ ---------------------- ---------------------------------------------------
  Brinkman \[[@B2]\]      Dutch                                                    144   65          66.8                     14.06                    ns                     Erosions on any radiograph during first 3 years

  Pawlik \[[@B10]\]       Polish                                                   91    63          51.7 (range 21-74)^\#^   4.7 ± 2.1                ns                     Erosions in chest, hands or feet

  Khanna \[[@B9]\]        Americans (Western US) and Mexican                       189   76          ns                       0.47 (0.3-0.71)\*        Sharp                  Erosion score ≥ 2 In hand/wrist or feet

  Rezaieyazdi \[[@B7]\]   Iranian                                                  34    n.s.        47.3 ± 13.8              4.0 ± 3.7                ns                     Erosions in hands

  Kazkaz \[[@B8]\]        Syrian                                                   156   80          44.02 ± 14.47            7.28 ± 4.87              Larsen                 Destruction score ≥ 2, right wrist

  Kazkaz \[[@B8]\]        French                                                   512   75          57.56 ± 14.67            10.05 ± 8.66             Larsen                 Destruction score ≥ 2, right wrist

  Ates \[[@B5]\]          Turkish                                                  98    80          50.8 ± 12                ns                       ns                     Erosions in hands or feet

  Nemec \[[@B6]\]         Caucasians from Moravian regions of the Czech Republic   130   75          56.21 (20.25-79)\*       11.08 (2.08-50.17)\*     Steinbrocker           Erosions of stage II-IV in hands

  Reneses \[[@B4]\]       Spanish                                                  134   70          50.4 ± 1.3               \< 1                     Sharp van der Heijde   Erosion at 1 year in hands, wrist or feet

  Hussein \[[@B3]\]       Egyptian                                                 172   100         47.4 ± 9.3               10.65 ± 7.9              Sharp                  ≥ 1 erosions in peripheral joints (hands or feet)

  Mosaad \[[@B1]\]        Egyptian                                                 122   80          39.9 ± 10.3              5.9 ± 5.1                Steinbrocker           Erosions in hands
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Age and disease duration are depicted as mean ± SD unless stated otherwise. \*Median (range); ^\#^mean (range); ns, not specified.

![**Meta-analysis results for the TNF -308G \> A variant**. Events indicate the number of patients with genotype GA or AA. M-H, Mantel-Haenszel.](ar4110-2){#F2}

*TNFA*expression and the role of the -308G \> A promoter polymorphism
---------------------------------------------------------------------

To assess whether the difference in radiologic joint damage between G-homozygotes and A-allele carriers could be explained at the level of expression of this cytokine, we measured the RNA expression levels of *TNFA*dependent on -308G \> A genotype in a sample of 66 patients with active RA. Among the sixty-six patients, forty-nine carried the GG genotype, fifteen were GA-heterozygotes, and two were A-homozygotes. Again, the GA and AA genotypes were merged and analyzed as one group. No difference in *TNFA*expression was observed between the GG group when compared to the GA+AA group (*P*= 0.420) (Figure [3](#F3){ref-type="fig"}).

![**Relative expression of the *TNFA*gene per genotype group**. The GA genotype group (*n*= 15) and the AA genotype group (*n*= 2) were combined and compared to the GG genotype group (*n*= 49). No difference in *TNFA*expression was observed between the GG group and the GA+AA group (*p*= 0.420).](ar4110-3){#F3}

Discussion
==========

Based on earlier literature, we tested the hypothesis that in RA, disease severity defined by the average DAS28 and radiologic joint damage, may be influenced by the *TNFA*-308G \> A genotype. Our own study and the meta-analysis indeed confirm that patients carrying the common GG genotype have worse radiologic outcomes. This could not be explained by differences in either disease activity, genotype-dependent *TNFA*expression, or the use of TNF blocking agents.

Our results show that the GG genotype is associated with a worse radiologic outcome, in spite of the fact that in our early inception cohort the radiologic progression after 9 years was similar in both genotypes. It would be of great interest to see if these results could be replicated in other early RA cohorts though the number of published studies hitherto is too small for a meta-analysis.

Many studies investigating the relationship between the -308G \> A promoter polymorphism and severity of RA and radiological joint damage report contradictive results \[[@B1]-[@B14]\]. Therefore, a meta-analysis offers a good alternative for evaluating the presence or absence of an association in situations where individual studies are inconclusive. Our meta-analysis indeed confirmed that the -308G \> A polymorphism is associated with the presence of erosions, with patients carrying the GA/AA genotypes having fewer erosions. Although the result of the meta-analysis is consistent with the results of our primary study, it is important to mention that there was significant heterogeneity in the studies included in the meta-analysis (*I*^2^= 53%). This could be caused by differences in study design, mean duration of RA, sample size and ethnicity. An additional reason is the assessment of the presence of erosions, which was assessed in radiographs of different joints (see Table [3](#T3){ref-type="table"}), though most studies included erosions in the hands. Also the definition of erosive disease differed between the studies, but the outcome used in the current study was the presence of any erosion in the joints examined. As we observed heterogeneity we also performed a random-effects meta-analysis. This yielded a similar OR but, as expected, a larger CI. Even so, both analyses point to a modest effect of the polymorphism on the development of joint damage.

In this study we also assessed whether the difference in radiologic joint damage between G- homozygotes and A-allele carriers could be explained by *TNFA*allele-specific differences in mRNA expression. Many studies have focused on the potential allele-specific expression of the *TNFA*gene and TNFα production. Helmig and co-workers reported that the -308G allele is associated with *TNFA*expression in a cohort of 178 healthy subjects \[[@B23]\]. In contrast, a recent meta-analysis in which 1,825 healthy subjects were investigated, reported no association between the -308G \> A polymorphism and TNF protein and mRNA levels \[[@B25]\]. However, this might still be the case for persons suffering from a disease. For instance, the study of Muoz-Valle, *et al*. (50 patients with osteoarthritis), and the study of Oregon-Romero, *et al*. (50 patients with RA) both report an association between the -308G allele and higher *TNFA*expression levels compared to the -308A allele \[[@B21],[@B22]\]. Nonetheless, our study does not support this hypothesis and shows that the effect of the -308G \> A variant on joint damage is not explained by allele-dependent expression in RA. Linkage disequilibrium (LD) could be an overall factor to explain this incongruent result if we assume that the -308G \> A variant is not functional. In fact, LD is strong in this area of the genome, and it is difficult to study the role of a single nucleotide polymorphism (SNP) in this region. Nevertheless, a published haplotype analysis including three SNPs (-857C \> T, -308G \> A, and -238G \> A) in the promoter of the *TNFA*gene also showed no association between the SNPs and circulating TNF levels or *TNFA*mRNA expression \[[@B25]\]. It is known that the LD in the *TNFA*region even extends much further and is in strong LD with the shared epitope (SE) \[[@B31]\]. This could explain some of the inconsistency in the findings, although the results of a study of Khanna and co-workers indicates an effect of the -308G \> A polymorphism on joint damage progression independently of the SE \[[@B9]\]. Our patients are not genotyped for the SE and we could not stratify for SE.

Conclusions
===========

Our data support an association between the *TNFA*-308GG genotype and joint damage, but not with disease activity or *TNFA*expression. Our meta-analysis shows that the effects of this polymorphism are modest, which makes it unsuitable as a single predictive marker for disease severity.
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